Medication for Addiction Treatment During COVID-19
As overdose rates rise, we need addiction treatment in hospitals now more than ever. This guidance outlines how to implement medication for addiction treatment (MAT) during predicted COVID-19 surges.
New HHS Practice Guidelines
Here’s the most important takeaway of the “HHS Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder”: All prescribers with a valid state license and DEA can register for an X wavier without mandatory training.
Blueprint for Hospital Opioid Use Disorder Treatment
This comprehensive resource is scalable for any health system, based on our model implemented at diverse sites that demonstrate feasibility at large and small, public and private, urban, and rural hospitals.
Buprenorphine Starts for Fentanyl Use
3 Feb 2022, 11:00 am
Emerging Trends Training Series
Presenters: Hannah Snyder, MD & Erik Andersen, MD
Facts vs Fear: As fentanyl spreads in many communities, buprenorphine is still an effective tool for treating patients with just a few clinical tweaks.